A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/28/2011	CN101180060B 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合 Combination treatment or prevention of proliferative diseases pyrimidylaminobenzamide amine compounds and imatinib
12/28/2011	CN101175532B 包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物 An antiparasitic and comprising one member selected from carveol, thymol, eugenol, camphor alcohol, carvacrol, pharmaceutical compositions α- or β- ionone ionone active ingredient
12/28/2011	CN101164558B 一种化瘀止痛药物组合物及其制备方法与用途 One kind of pain medication circulation composition and preparation method and use
12/28/2011	CN101138548B 聚乙二醇衍生化磷脂包载的长春瑞滨纳米胶束制剂 Polyethylene glycol derivatized phospholipids entrapped micelle formulation of vinorelbine
12/28/2011	CN101057888B 一种调节免疫力的中药组合物及其制备方法和应用 An adjustment of Chinese medicine composition and preparation method and application of immunity
12/28/2011	CN101007000B 异黄酮化合物的制药用途以及含有它们的组合物 Isoflavone compounds and pharmaceutical use of the compositions containing them
12/27/2011	US8084645 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
12/27/2011	US8084618 Heterocyclic compounds and methods of use
12/27/2011	US8084605 Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
12/27/2011	US8084591 Blood coagulation factor; nucleotide encodes polypeptide; amino acid sequence differs from wild-type FVII or FVIIa; amino acid residue attachment group for non-polypeptide moiety has been introduced or removed; host cell is gammacarboxylating capable of in vivo glycosylation; coagulation disorders
12/27/2011	US8084250 Defensin-antigen fusion proteins
12/27/2011	US8084249 Vector
12/27/2011	US8084049 Complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
12/27/2011	US8084031 Method for the treatment of inflammatory disorders
12/27/2011	US8084029 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
12/27/2011	US8084015 Immunostimulatory complex of a cationic peptide immunogen and anionic CpG single-stranded DNA oligonucleotide
12/22/2011	WO2011160136A2 Progesterone containing oral dosage forms and related methods
12/22/2011	WO2011160132A2 Detection of epha3 as a marker of the presence of a solid tumor
12/22/2011	WO2011159981A2 Lung regeneration using cord blood-derived hematopoietic stem cells
12/22/2011	WO2011159980A1 Anti-axl antibodies and methods of use
12/22/2011	WO2011159928A2 Anti-dr4 agonist antibodies
12/22/2011	WO2011159917A2 Growth hormone secretatogue receptor antagonists and uses thereof
12/22/2011	WO2011159847A2 Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
12/22/2011	WO2011159771A2 Compositions and methods for treating cancer
12/22/2011	WO2011159769A2 Indane estrogen receptor modulators and uses thereof
12/22/2011	WO2011159685A2 Inhibition of wdr5 interaction with its binding partners and therapeutic methods
12/22/2011	WO2011159100A2 Anti-cancer pharmaceutical composition
12/22/2011	WO2011158931A1 Useful salts of indazole derivative
12/22/2011	WO2011158924A1 Inhibitor of expression of dominant allele
12/22/2011	WO2011158689A1 Agent for reducing acetaldehyde in oral cavity
12/22/2011	WO2011158206A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
12/22/2011	WO2011158019A1 Polypeptide vaccine
12/22/2011	WO2011157802A1 Pharmaceutical preparation comprising actinomycin d for the treatment of b-cll in patients having del (17)
12/22/2011	WO2011157724A1 S100a4 antibodies and therapeutic uses thereof
12/22/2011	WO2011157688A1 Substituted triazolopyridines
12/22/2011	WO2011157450A1 New polymorphic form of imatinib base and preparation of salts thereof
12/22/2011	WO2011156970A1 Uses of mtea in diagnosis and treatment of malignant tumor
12/22/2011	WO2011156908A1 Methods of treating or preventing estrogen-related diseases
12/22/2011	WO2011156860A1 IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Rα) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX
12/22/2011	WO2011134444A3 Substitution derivatives of n6-benzyladenosine-5´-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds
12/22/2011	WO2011133886A3 Production of heteromultimeric proteins
12/22/2011	WO2011128434A3 Treatment of endocrine resistant breast cancer
12/22/2011	WO2011119345A3 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/22/2011	WO2011112921A3 Sparc angiogenic domain and methods of use
12/22/2011	WO2011112902A3 Nonviral gene delivery vector iopamidol, protamine, ethiodized oil reagent (viper)
12/22/2011	WO2011112689A9 Salts of an indazolylpyrrolotriazine
12/22/2011	WO2011103011A3 Gene fusion targeted therapy
12/22/2011	WO2011097594A3 Therapeutic methods and compositions involving allosteric kinase inhibition
12/22/2011	WO2011094671A3 N-terminally conjugated polypeptides for targeted therapy and diagnosis
12/22/2011	WO2011088456A3 Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
12/22/2011	WO2010111891A8 Modified oligo-nucleic acid molecule, preparation method and uses thereof
12/22/2011	US20110313233 Down-regulation of cold shock proteins for cancer treatment
12/22/2011	US20110313230 Specific binding proteins and uses thereof
12/22/2011	US20110313229 Therapy Targeting Cancer Stem Cells
12/22/2011	US20110313045 Histone deacetylases, and uses related thereto
12/22/2011	US20110313044 Polymorphs of Suberoylanilide Hydroxamic Acid
12/22/2011	US20110313041 Food supplements on the basis of pantothenic acid
12/22/2011	US20110313039 Method for increasing endogenous plasmalogen levels in mammals
12/22/2011	US20110313032 Competitive inhibitors of type ii dehydroquinase enzyme
12/22/2011	US20110313030 Pkr activation via hybridization chain reaction
12/22/2011	US20110313028 Suppressor of ap-1
12/22/2011	US20110313025 Methods and compositions involving mirna and mirna inhibitor molecules
12/22/2011	US20110313021 Method to rapidly identify critical p53 target genes that can be utilized for therapeutic intervention
12/22/2011	US20110313020 UsiRNA Complexes
12/22/2011	US20110313018 Cancer related gene, lgn/gpsm2
12/22/2011	US20110313016 Treatment of Intestinal Conditions
12/22/2011	US20110313010 Combination of local temozolomide with local bcnu
12/22/2011	US20110313004 Deuterated pyridinones
12/22/2011	US20110312997 Inhibition of WDR5 Interaction with Its Binding Partners
12/22/2011	US20110312992 Inhibitors of C-Kit and Uses Thereof
12/22/2011	US20110312988 Sns-595 and methods of using the same
12/22/2011	US20110312984 Stat3 inhibitors
12/22/2011	US20110312982 Cancer Treatment Method
12/22/2011	US20110312981 Predictive marker for egfr inhibitor treatment
12/22/2011	US20110312980 Small-molecule Hsp90 Inhibitors
12/22/2011	US20110312979 Fused pyrrole derivatives as pi3k inhibitors
12/22/2011	US20110312974 Heteroaryl antagonists of prostaglandin d2 receptors
12/22/2011	US20110312969 Compounds for treating cancer
12/22/2011	US20110312968 Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
12/22/2011	US20110312965 Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
12/22/2011	US20110312963 P38 map kinase inhibitors
12/22/2011	US20110312960 Pyrazine derivatives and use as pi3k inhibitors
12/22/2011	US20110312959 Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC
12/22/2011	US20110312956 ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
12/22/2011	US20110312955 Triazine compounds as pi3 kinase and mtor inhibitors
12/22/2011	US20110312951 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof
12/22/2011	US20110312950 CYCLIC INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
12/22/2011	US20110312944 Heterocyclic Compounds Which Modulate The CB2 Receptor
12/22/2011	US20110312943 Aurora kinase inhibitors for inhibiting mitotic progression
12/22/2011	US20110312942 Aurora kinase inhibitors for inhibiting mitotic progression
12/22/2011	US20110312941 1,4-disubstituted piperidines as vasopressin receptor via antagonists
12/22/2011	US20110312940 Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (p13-kinases) inhibitor
12/22/2011	US20110312939 New chemical compounds
12/22/2011	US20110312936 Cyclohexyl-azetidinyl antagonists of ccr2
12/22/2011	US20110312935 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents
12/22/2011	US20110312934 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
12/22/2011	US20110312930 Aryl compounds with aminoalkyl substituents and their use
12/22/2011	US20110312928 Progesterone Containing Oral Dosage Forms and Related Methods
12/22/2011	US20110312926 2-(N-Substituted Piperazinyl) Steroid Derivatives
12/22/2011	US20110312925 Methods of treating or preventing estrogen-related diseases

1 ... 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 ... 2211